NED TALK 2021: Current Therapeutic and Supportive Care Strategies for MDS and AML

NED TALK 2021: Current Therapeutic and Supportive Care Strategies for MDS and AML

Saturday, November 13, 2021
Webinar -- 8:30 AM ET
https://www.clinicaloptions.com/MDSAMLNED2021Join1

Agenda

  • Welcome and Introduction
  • NED Talk 1: Novel Therapeutic Approaches for the Treatment of Lower-Risk MDS
  • NED Talk 2: Latest Guidance on the Treatment of Higher-Risk MDS and Managing Relapsed/Refractory MDS
  • Audience Question and Answer
  • NED Talk 3: Optimizing AML Therapy for Unfit Patients
  • NED Talk 4: Targeted Treatment Options for Patients With FLT3 or IDH1/2 Mutations
  • Audience Question and Answer
  • NED Talk 5: Induction and Maintenance Therapy for Younger Patients With AML Without Targetable Mutations
  • NED Talk 6: Managing Patients With Relapsed/Refractory AML
  • Audience Question and Answer

Faculty

Faculty
Ashley Leak Bryant, PhD, RN, OCN, FAAN

Faculty
Sara M. Tinsley, PhD, ARNP, AOCN

Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida

Goal Statement
MDS: The goal of this program is to improve the knowledge, confidence, and competence of nurses, physician assistants and other healthcare professionals to optimally care for patients with MDS.
AML: The goal of this activity is to improve the knowledge, confidence, and competence of nurses, physician assistants and other healthcare providers to optimally care for patients with AML.

Target Audience
MDS: This educational program is intended for nurses, physician assistants and other healthcare professionals specializing in hematology/oncology involved in the care of patients with MDS.
AML: This educational program is intended for nurses, physician assistants and other healthcare professionals specializing in hematology/oncology involved in care of patients with AML.

Learning Objectives
Upon completion of this activity, participants should be able to:

MDS:

  • Evaluate emerging treatment options for the management of patients with low-risk, intermediate-risk, or high-risk MDS
  • Plan therapeutic strategies for patients with MDS after failure of HMAs
  • Manage MDS-related anemia through the use of novel agents
  • Identify patients with MDS who are candidates for enrollment on ongoing clinical trials

AML:

  • Provide patient-focused education on the available clinical data and new therapeutic options for the individualized treatment of AML
  • Discuss with patients the rationale for targeted therapies for specific patients with AML
  • Evaluate individualized treatment strategies for older patients through consideration of the available clinical data as well as risk assessment, comorbidities, and patient preferences
  • Develop a proactive management plan for adverse events associated with recently approved agents and novel combinations used to treat AML
  • Manage the physical, emotional, and social challenges experienced by patients diagnosed with AML through all stages of their disease

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Education

Designation of Credit

The maximum number of hours awarded for this Continuing Nursing Education activity is 2.25 contact hours.

Physician Assistant Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.25 AAPA Category 1 CME credits. PAs should only claim commensurate with the extent of their participation.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.